Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Aprea Therapeutics ( (APRE) ) is now available.
On March 30, 2026, Aprea Therapeutics entered into a securities purchase agreement for an oversubscribed private placement of pre-funded and common stock warrants to raise approximately $30 million in gross proceeds, with closing expected on or about March 31, 2026. The deal, led by Soleus Capital alongside new and existing investors, includes lock-ups for directors and officers, resale registration commitments and issuance and variable-rate financing restrictions that limit near-term equity dilution mechanisms.
The warrants cover up to roughly 74.4 million shares combined, with nominally priced pre-funded warrants and common warrants exercisable immediately at $0.683 per share, generally expiring by December 31, 2029. Aprea plans to use the net proceeds for general corporate purposes and R&D, including expanding enrollment in its ACESOT-1051 Phase 1 trial of APR-1051 into uterine serous carcinoma and Cyclin E-overexpressing, platinum-resistant ovarian cancer, and expects the financing to extend its cash runway into the first quarter of 2028.
Also on March 30, 2026, the company announced confirmation of a partial response in the ongoing ACESOT-1051 trial evaluating APR-1051, signaling emerging clinical activity for its lead WEE1 inhibitor. In connection with the new financing, Aprea amended a January 2026 securities purchase agreement to modify prior issuance and variable-rate transaction restrictions, aligning its capital structure and investor protections with the latest private placement.
The most recent analyst rating on (APRE) stock is a Hold with a $0.66 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Neutral.
The score is held down primarily by weak fundamentals—ongoing losses, cash burn, and inconsistent/limited revenue—alongside a technically weak price trend below key moving averages. Offsetting factors include low leverage and positive corporate updates (early clinical activity for APR-1051 and extended cash runway via financing), but these are not yet sufficient to outweigh the current financial and trend risks.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company focused on discovering and developing targeted therapies for patients with biomarker-defined cancers. Its lead programs are APR-1051, an oral small-molecule WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, in development for solid tumors including ovarian, endometrial, colorectal and head and neck cancers.
The company’s approach aims to exploit vulnerabilities associated with cancer cell mutations to kill tumors while sparing healthy cells. This platform underpins a pipeline targeting multiple tumor types and positions Aprea within the high-growth market for next-generation, biomarker-driven oncology treatments.
Average Trading Volume: 2,175,840
Technical Sentiment Signal: Sell
Current Market Cap: $7.82M
See more insights into APRE stock on TipRanks’ Stock Analysis page.